Because several of the GLP‐1 RAs have been shown to reduce the risk of cardiovascular disease (CVD) in T2DM, and they typically do not increase the risk of adverse events commonly seen with insulin therapy such as weight gain and hypoglycaemia, they are recommended as the first injectable option in patients with CVD, heart failure, or chronic kidney disease, or in patients with a compelling need to reduce risk of hypoglycaemia; and for patients in whom weight gain maybe a concern.2 The gene discussed is INS; the disease is chronic kidney disease.